89 patents
Utility
ANTI-CD73 Antibodies and Methods of Use Thereof
28 Dec 23
The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function.
Nicholas S. WILSON, Jeremy D. Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
Filed: 26 May 23
Utility
Antibodies and Methods of Use Thereof
21 Dec 23
The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies.
Nicholas S. WILSON, Jeremy D. WAIGHT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Takemasa TSUJI, Olivier LÉGER, Dennis J. UNDERWOOD, Marc VAN DIJK
Filed: 22 Aug 22
Utility
Antibodies and Methods of Use Thereof
14 Dec 23
The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies.
Nicholas S. WILSON, Jeremy D. WAIGHT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Takemasa TSUJI, Olivier LÉGER, Dennis J. UNDERWOOD, Marc VAN DIJK
Filed: 22 Aug 22
Utility
Anti-TIM-3 antibodies and methods of use thereof
12 Dec 23
Antibodies that specifically bind to TIM 3 and antagonize TIM-3 function pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.
Marc van Dijk, Ekaterina Vladimirovna Breous-Nystrom, Nicholas Stuart Wilson, Jeremy Dale Waight, Dennis John Underwood
Filed: 2 Mar 20
Utility
ANTI-CTLA-4 Antibodies and Methods of Use Thereof
19 Oct 23
The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function.
Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, David SCHAER, Jedd David WOLCHOK, Taha MERGHOUB, Nicholas S. WILSON, David Adam SAVITSKY, Mark Arthur FINDEIS, Dennis J. UNDERWOOD, Jean-Marie CUILLEROT, Igor Proscurshim, Olga SHEBANOVO
Filed: 21 Mar 23
Utility
Anti-TIGIT and anti-CD96 antibodies
8 Aug 23
The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT).
Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
Filed: 10 Aug 22
Utility
Anti-CD73 antibodies and methods of use thereof
4 Jul 23
The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function.
Nicholas Stuart Wilson, Jeremy Dale Waight, Shawn Michael Jennings, Olga Ignatovich, Emmanuel Cyrille Pascal Briend, Benjamin Maxime Morin, Oliver Schon, Spencer Campbell
Filed: 8 Mar 19
Utility
Anti-CTLA-4 antibodies and methods of use thereof
2 May 23
The instant disclosure provides antibodies that specifically bind to CTLA-4 (e.g., human CTLA-4) and antagonize CTLA-4 function.
Marc van Dijk, Cornelia Anne Mundt, Gerd Ritter, David Schaer, Jedd David Wolchok, Taha Merghoub, Nicholas Stuart Wilson, David Adam Savitsky, Mark Arthur Findeis, Dennis John Underwood, Jean-Marie Cuillerot, Igor Proscurshim, Olga Shebanova
Filed: 14 Dec 20
Utility
Methods of Administering ANTI-OX40 Antibodies
6 Apr 23
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies.
Marc VAN DIJK, Ekaterina V. BREOUS-NYSTROM, Volker SEIBERT, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Hao TANG, David A. SAVITSKY, Jeremy WAIGHT, Nicholas S. WILSON
Filed: 8 Sep 22
Utility
Identification of MHC Class I Phospho-peptide Antigens from Breast Cancer Utilizing Shla Technology and Complementary Enrichment Strategies
23 Feb 23
The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides.
Donald F. Hunt, Andrew Norris, Ann Michelle English, Jeffrey Shabanowitz, William H. Hildebrand, Oriana E. Hawkins
Filed: 8 Jul 22
Utility
Anti-gitr Antibodies and Methods of Use Thereof
9 Feb 23
The present disclosure provides antibodies that specifically bind to human glucocorticoid-induced TNFR family related receptor (GITR) and compositions comprising such antibodies.
Ana M. GONZALEZ, Nicholas S. Wilson, Dennis J. Underwood, Volker Seibert, Olivier Léger, Marc Van Dijk, Roberta Zappasodi, Taha Merghoub, Jedd David Wolchok, David Schaer, Gerd Ritter, Takemasa Tsuji
Filed: 22 Jun 22
Utility
Anti-tigit Antibodies, ANTI-CD96 Antibodies, and Methods of Use Thereof
19 Jan 23
The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT).
Dhan Sidhartha Chand, Zahra Jawad, Olga Ignatovich, Nicola Anne Ramsay, Spencer Campbell, Beth Wensley, Emmanuel Cyrille Pascal Briend, K. Mark Bushell, Benjamin Maxime Morin, Veronica Franciszka Ilkow
Filed: 10 Aug 22
Utility
Anti-tigit Antibodies and Methods of Use Thereof
8 Dec 22
The instant disclosure provides isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT).
Olga IGNATOVICH, K. Mark BUSHELL, Dhan Sidhartha CHAND, Beth WENSLEY
Filed: 4 May 22
Utility
ANTI-OX40 Antibodies, Anti-gitr Antibodies, and Methods of Use Thereof
8 Dec 22
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies.
Nicholas S. WILSON, Jeremy D. WAIGHT, Dennis J. UNDERWOOD, Ekaterina V. BREOUS-NYSTROM, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Marc VAN DIJK
Filed: 9 May 22
Utility
ANTI-OX40 Antibodies, Anti-gitr Antibodies, and Methods of Use Thereof
1 Dec 22
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and/or human GITR receptor (GITR), including multispecific antibodies that bind, e.g., to OX40 and GITR, and compositions comprising such antibodies.
Nicholas S. WILSON, Jeremy D. WAIGHT, Dennis J. UNDERWOOD, Ekaterina V. BREOUS-NYSTROM, Gerd RITTER, David SCHAER, Daniel HIRSCHHORN-CYMERMAN, Taha MERGHOUB, Marc VAN DIJK
Filed: 9 May 22
Utility
ANTI-PD-1 Antibodies and Methods of Use Thereof
24 Nov 22
The instant disclosure provides antibodies that specifically bind to human PD-1 and antagonize PD-1 function.
Marc VAN DIJK, Cornelia Anne MUNDT, Gerd RITTER, Jedd David WOLCHOK, Taha MERGHOUB, Roberta ZAPPASODI, Rikke Baek HOLMGAARD, David SCHAER, David Adam SAVITSKY, Nicholas Stuart WILSON
Filed: 9 May 22
Utility
Methods of administering anti-OX40 antibodies
18 Oct 22
The present disclosure provides antibodies that specifically bind to human OX40 receptor (OX40) and compositions comprising such antibodies.
Marc Van Dijk, Ekaterina V. Breous-Nystrom, Volker Seibert, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Hao Tang, David A. Savitsky, Jeremy Waight, Nicholas S. Wilson
Filed: 3 Mar 20
Utility
Antibodies and methods of use thereof
20 Sep 22
The present disclosure provides multispecific (e.g., bispecific) antibodies that specifically bind to human GITR and/or human OX40 as well as compositions comprising such antibodies.
Nicholas S. Wilson, Jeremy D. Waight, Gerd Ritter, David Schaer, Daniel Hirschhorn-Cymerman, Taha Merghoub, Ekaterina V. Breous-Nystrom, Volker Seibert, Takemasa Tsuji, Olivier Léger, Dennis J. Underwood, Marc Van Dijk
Filed: 2 Dec 16
Utility
Antigenic Polypeptides and Methods of Use Thereof
1 Sep 22
Provided are novel antigenic polypeptides comprising tumor-associated peptides, and compositions comprising the same.
Benjamin Maxime MORIN, Mark Arthur FINDEIS, Bishnu JOSHI
Filed: 24 Jan 22
Utility
ANTI-CTLA-4 Antibodies and Methods of Use Thereof
25 Aug 22
The instant disclosure provides antibodies that specifically bind to human CTLA-4 and antagonize CTLA-4 function.
Marc Van DIJK, Cornelia Anne MUNDT, Gerd RITTER, David SCHAER, Jedd David WOLCHOK, Taha MERGHOUB, David Adam SAVITSKY, Nicholas Stuart WILSON
Filed: 24 Jan 22